RegulatoryJun 8, 2026, 06:31 AM
Artiva's AlloNK Gets FDA RMAT for RA; Strong Clinical Data at EULAR
AI Summary
Artiva Biotherapeutics announced that its lead candidate, AlloNK (AB-101) combined with rituximab, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for refractory rheumatoid arthritis (RA). This designation supports an expedited development and review process. The company also presented robust clinical, safety, and translational data at the EULAR 2026 Congress, demonstrating deep B-cell depletion and meaningful clinical responses across RA, Sjögren disease, and systemic sclerosis. With an extended cash runway into 2029, Artiva is well-positioned to advance its planned Phase 3 trial in refractory RA.
Key Highlights
- FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory rheumatoid arthritis.
- AlloNK showed 71% ACR50 response at six months in company-sponsored Phase 2a rheumatoid arthritis trial.
- Pooled rheumatoid arthritis data (21 patients) showed clinical responses as early as three months, deepening at six months.
- No cytokine release syndrome (CRS) or ICANS observed in 55 autoimmune patients treated with AlloNK plus rituximab.
- Complete B-cell depletion by Day 13 observed in all 51 evaluable autoimmune patients.
- Cash runway extended into 2029 following recent financing.
- Artiva plans to initiate a Phase 3 registrational trial in refractory rheumatoid arthritis in 2026.
Price Impact
More from ARTV